Search

Your search keyword '"Bes, Marta"' showing total 49 results
Start Over Author "Bes, Marta"
49 results on '"Bes, Marta"'

2. Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017-2020

Author

Bes, Marta, Costafreda, Maria I., Riveiro-Barciela, Mar, Piron, Maria, Rico, Angie, Quer, Josep, Puig, Lluis, and Sauleda, Silvia

Subjects
Catalonia, Spain -- Health aspects, Hepatitis E -- Statistics -- Risk factors -- Diagnosis, Blood transfusion -- Statistics -- Complications and side effects, Blood donors -- Statistics, Medical screening -- Statistics, Health
Abstract

Hepatitis E virus (HEV; family Hepeviridae, genus Orthohepevirus) (1) is an RNA virus that causes acute viral hepatitis in humans. Five HEV genotypes are known to infect humans. Genotypes 1 [...]

Published
2022
Full Text
View/download PDF

3. A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysis

Author

Köhler, Bruno, primary, Bes, Marta, additional, Chan, Henry Lik-Yuen, additional, Esteban, Juan Ignacio, additional, Piratvisuth, Teerha, additional, Sukeepaisarnjaroen, Wattana, additional, Tanwandee, Tawesak, additional, Thongsawat, Satawat, additional, Mang, Anika, additional, Morgenstern, David, additional, Swiatek-de Lange, Magdalena, additional, and Dayyani, Farshid, additional

Published
2024
Full Text
View/download PDF

5. Discovery of a haptoglobin glycopeptides biomarker panel for early diagnosis of hepatocellular carcinoma

Author

Kohansal-Nodehi, Mahdokht, primary, Swiatek-de Lange, Magdalena, additional, Kroeniger, Konstantin, additional, Rolny, Vinzent, additional, Tabarés, Glòria, additional, Piratvisuth, Teerha, additional, Tanwandee, Tawesak, additional, Thongsawat, Satawat, additional, Sukeepaisarnjaroen, Wattana, additional, Esteban, Juan Ignacio, additional, Bes, Marta, additional, Köhler, Bruno, additional, Chan, Henry Lik-Yuen, additional, and Busskamp, Holger, additional

Published
2023
Full Text
View/download PDF

7. Comparison of Extracellular Vesicle Isolation Methods for miRNA Sequencing

Author

Llorens-Revull, Meritxell, primary, Martínez-González, Brenda, additional, Quer, Josep, additional, Esteban, Juan Ignacio, additional, Núñez-Moreno, Gonzalo, additional, Mínguez, Pablo, additional, Burgui, Idoia, additional, Ramos-Ruíz, Ricardo, additional, Soria, María Eugenia, additional, Rico, Angie, additional, Riveiro-Barciela, Mar, additional, Sauleda, Silvia, additional, Piron, María, additional, Corrales, Irene, additional, Borràs, Francesc E., additional, Rodríguez-Frías, Francisco, additional, Rando, Ariadna, additional, Ramírez-Serra, Clara, additional, Camós, Silvia, additional, Domingo, Esteban, additional, Bes, Marta, additional, Perales, Celia, additional, and Costafreda, Maria Isabel, additional

Published
2023
Full Text
View/download PDF

8. A new biomarker panel for differential diagnosis of cholangiocarcinoma: results from an exploratory analysis

Author

Köhler, Bruno, primary, Bes, Marta, additional, Chan, Henry LY, additional, Esteban Mur, Juan Ignacio, additional, Piratvisuth, Teerha, additional, Sukeepaisarnjaroen, Wattana, additional, Tanwandee, Tawesak, additional, Mang, Anika, additional, Morgenstern, David, additional, Lange, Magdalena Swiatek-de, additional, and Dayyani, Farshid, additional

Published
2023
Full Text
View/download PDF

9. Specific Plasma MicroRNA Signatures Underlying the Clinical Outcomes of Hepatitis E Virus Infection

Author

Costafreda, Maria I., primary, Sauleda, Silvia, additional, Riveiro-Barciela, Mar, additional, Rico, Angie, additional, Llorens-Revull, Meritxell, additional, Guix, Susana, additional, Pintó, Rosa M., additional, Bosch, Albert, additional, Rodríguez-Frías, Francisco, additional, Rando, Ariadna, additional, Piron, Maria, additional, and Bes, Marta, additional

Published
2023
Full Text
View/download PDF

10. Specific Plasma MicroRNA Signatures Underlying the Clinical Outcomes of Hepatitis E Virus Infection

Author

Costafreda Salvany, Maria Isabel, Sauleda, Silvia, Riveiro Barciela, Mar, Rico, Angie, Llorens-Revull, Meritxell, Guix, Susana, Pintó, Rosa M., Bosch, Albert, Rodríguez Frías, Francisco, Rando-Segura, Ariadna, Piron, Maria, Bes, Marta, and Universitat Autònoma de Barcelona. Departament de Medicina

Subjects
Microbiology (medical), Micro RNAs, General Immunology and Microbiology, Ecology, Physiology, Cell Biology, Infection outcomes, Microrna, MicroRNAs, Infectious Diseases, Prognostic indicators, Genetics, Hepatitis E virus, RNA, Virus de l'hepatitis E, Diagnostics
Abstract

The pathogenic mechanisms determining the diverse clinical outcomes of HEV infection (e.g., self-limiting versus chronic or symptomatic versus asymptomatic) are not yet understood. Because specific microRNA signatures during viral infection inform the cellular processes involved in virus replication and pathogenesis, we investigated plasma microRNA profiles in 44 subjects, including patients with symptomatic acute (AHE, n = 7) and chronic (CHE, n = 6) hepatitis E, blood donors with asymptomatic infection (HEV BDs, n = 9), and anti-HEV IgG + IgM − (exposed BDs, n = 10) and anti-HEV IgG − IgM − (naive BDs, n = 12) healthy blood donors. By measuring the abundance of 179 microRNAs in AHE patients and naive BDs by reverse transcription-quantitative PCR (RT-qPCR), we identified 51 potential HEV-regulated microRNAs (P value adjusted for multiple testing by the Benjamini-Hochberg correction [ P ] < 0.05). Further analysis showed that HEV genotype 3 infection is associated with miR-122, miR-194, miR-885, and miR-30a upregulation and miR-221, miR-223, and miR-27a downregulation. AHE patients showed significantly higher levels of miR-122 and miR-194 and lower levels of miR-221, miR-27a, and miR-335 than HEV BDs. This specific microRNA signature in AHE could promote virus replication and reduce antiviral immune responses, contributing to the development of clinical symptoms. We found that miR-194, miR-335, and miR-221 can discriminate between asymptomatic HEV infections and those developing acute symptoms, whereas miR-335 correctly classifies AHE and CHE patients. Our data suggest that diverse outcomes of HEV infection result from different HEV-induced microRNA dysregulations. The specific microRNA signatures described offer novel information that may serve to develop biomarkers of HEV infection outcomes and improve our understanding of HEV pathogenesis, which may facilitate the identification of antiviral targets. IMPORTANCE There is increasing evidence that viruses dysregulate the expression and/or secretion of microRNAs to promote viral replication, immune evasion, and pathogenesis. In this study, we evaluated the change in microRNA abundance in patients with acute or chronic HEV infection and asymptomatic HEV-infected blood donors. Our results suggest that different HEV-induced microRNA dysregulations may contribute to the diverse clinical manifestations of HEV infection. The specific microRNA signatures identified in this study hold potential as predictive markers of HEV infection outcomes, which would improve the clinical management of hepatitis E patients, particularly of those developing severe symptoms or chronic infections. Furthermore, this study provides new insights into HEV pathogenesis that may serve to identify antiviral targets, which would have a major impact because no effective treatments are yet available

Published
2023

11. HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience

Author

Piron, Maria, Salvador, Fernando, Caballero Requero, Estrella, Sánchez-Montalvá, Adrián, Bes, Marta, Casamitjana, Natàlia, Puig Sanz, Lluís, Molina Romero, Israel, Sauleda, Silvia, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Piron M, Bes M, Sauleda S] Banc de Sang i Teixits de Catalunya (Blood and Tissue Bank of Catalonia, BST), Transfusion Safety Laboratory, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREhd), Instituto de Salud Carlos III, Madrid, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Salvador F, Sánchez-Montalvá A, Molina I] Centre de Salut Internacional i Malalties Transmissibles Drassanes-Vall d'Hebron Hospital Universitari, Barcelona, Spain. Servei de Malalties Infecciones, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. [Caballero E] Laboratori de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Casamitjana N] Banc de Sang i Teixits de Catalunya (Blood and Tissue Bank of Catalonia, BST), Transfusion Safety Laboratory, Barcelona, Spain. [Puig L] Banc de Sang i Teixits de Catalunya (Blood and Tissue Bank of Catalonia, BST), Transfusion Safety Laboratory, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREhd), Instituto de Salud Carlos III, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Adult, Male, personas::donantes de tejidos::donantes de sangre [DENOMINACIONES DE GRUPOS], Blood Donors, Virus Diseases::RNA Virus Infections::Retroviridae Infections::Deltaretrovirus Infections [DISEASES], Deltaretrovirus, Virology, Humans, Malalties transmissibles, Infeccions per retrovirus, transfusion, Other subheadings::Other subheadings::/transmission [Other subheadings], Human T-lymphotropic virus 1, screening, virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Deltaretrovirus [ENFERMEDADES], Human T-lymphotropic virus 2, HTLV-I Infections, HTLV-1/2, blood donors, leukoreduction, Spain, Infectious Diseases, Persons::Tissue Donors::Blood Donors [NAMED GROUPS], HTLV-1, HTLV-II Infections, Otros calificadores::Otros calificadores::/transmisión [Otros calificadores], Female, Donants de sang
Abstract

Spain; Screening; Transfusion España; Cribado; Transfusión Espanya; Cribratge; Transfusió Human T-cell lymphotropic virus type 1 and 2 (HTLV-1/2) screening is not mandatory in Spanish blood banks. In Catalonia, selective screening was introduced in 2008, followed by universal screening in 2011. We present herein a 10-year experience of HTLV testing in blood donors. HTLV-1/2 selective screening was performed using Ortho-Clinical Diagnostics HTLV-I/HTLV-II Ab-Capture ELISA between February 2008 and May 2009, then Abbott Prism HTLV-I/ HTLV-II assay until December 2010. Abbott Architect rHTLV-I/II assay was then used for HTLV-1/2 universal screening in pooled samples. INNO-LIA HTLV I/II Score (Fujirebio) and in-house HTLV-1/2 proviral DNA real-time PCR were used in reactive samples. Follow-up was offered to confirm HTLV-1/2 donors in Vall d’Hebron Hospital. Between 2008 and 2017, 51 blood donors were confirmed HTLV positive (46 HTLV-1, 4 HTLV-2 and 1 HTLV) out of 2,114,891 blood donations (1 in 41,468). Sixty-nine percent were female, median age was 40 years and most were born in Latin America (69%), followed by Europe (25%), Africa (4%) and Asia (2%). Screening of relatives and partners identified 12 additional HTLV-1 cases. Lookback studies did not show any HTLV-1/2 transmission. HTLV infections found in blood donors mirror epidemiological changes in the population of Spain. Consequently, HTLV should be considered a potential risk for recipients and calls for the design of optimal strategies to ensure transfusion safety. A.S.-M was supported by a postdoctoral grant “Juan Rodés” (JE18/00022) from the Instituto de Salud Carlos III through the Spanish Ministry of Economy and Competitiveness.

Published
2022

12. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma

Author

Malik, Juliane, primary, Klammer, Martin, additional, Rolny, Vinzent, additional, Chan, Henry Lik-Yuen, additional, Piratvisuth, Teerha, additional, Tanwandee, Tawesak, additional, Thongsawat, Satawat, additional, Sukeepaisarnjaroen, Wattana, additional, Esteban, Juan Ignacio, additional, Bes, Marta, additional, Köhler, Bruno, additional, and Swiatek-de Lange, Magdalena, additional

Published
2022
Full Text
View/download PDF

14. ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype

Author

Roade, Luisa, primary, Riveiro-Barciela, Mar, additional, Palom, Adriana, additional, Rodríguez-Frías, Francisco, additional, Bes, Marta, additional, Rando, Ariadna, additional, Salcedo, María Teresa, additional, Casillas, Rosario, additional, Vargas-Accarino, Elena, additional, Tabernero, David, additional, Sauleda, Silvia, additional, Esteban, Rafael, additional, and Buti, María, additional

Published
2022
Full Text
View/download PDF

16. Efficacy of early transfusion of convalescent plasma with high‐titer SARS‐CoV ‐2 neutralizing antibodies in hospitalized patients with COVID ‐19

Author

Sanz, Cristina, primary, Nomdedeu, Meritxell, additional, Pereira, Arturo, additional, Sauleda, Silvia, additional, Alonso, Rodrigo, additional, Bes, Marta, additional, Brillembourg, Helena, additional, García‐Vidal, Carolina, additional, Millan, Anna, additional, Martínez‐Llonch, Nuria, additional, Pirón, María, additional, Puerta‐Alcalde, Pedro, additional, Puig, Lluis, additional, Rico, Veronica, additional, and Soriano, Alex, additional

Published
2022
Full Text
View/download PDF

17. Clinical evaluation of the Procleix SARS-CoV-2 assay, a sensitive, high-throughput test that runs on an automated system

Author

Sauleda, Silvia, primary, Palacios, Lourdes, additional, Brès, Vanessa, additional, Piñana, Maria, additional, Alonso-Hernandez, Lorena, additional, Bes, Marta, additional, Piron, Maria, additional, Entrena, Edurne, additional, Minguez-Micolau, Antonio M., additional, Marimón, Jose Maria, additional, Gurrola, Adrian, additional, Soria, Gloria, additional, Puig, Lluís, additional, Antón, Andrés, additional, Pumarola, Tomás, additional, and Linnen, Jeffrey M., additional

Published
2022
Full Text
View/download PDF

20. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case‐Control Study

Author

Piratvisuth, Teerha, primary, Tanwandee, Tawesak, additional, Thongsawat, Satawat, additional, Sukeepaisarnjaroen, Wattana, additional, Esteban, Juan Ignacio, additional, Bes, Marta, additional, Köhler, Bruno, additional, He, Ying, additional, Swiatek‐de Lange, Magdalena, additional, Morgenstern, David, additional, and Chan, Henry Lik‐Yuen, additional

Published
2021
Full Text
View/download PDF

21. Detection of Nonenveloped Hepatitis E Virus in Plasma of Infected Blood Donors.

Author

Costafreda, Maria Isabel, Sauleda, Silvia, Rico, Angie, Piron, Maria, and Bes, Marta

Subjects
HEPATITIS E virus, BLOOD plasma, BLOOD donors, BLOOD products, LIVER enzymes, HEPATITIS viruses, HEPATITIS E, RNA, VIRAL antibodies
Abstract

Background: Transfusion-transmitted hepatitis E virus (HEV) infections have raised many concerns regarding the safety of blood products. To date, enveloped HEV particles have been described in circulating blood, whereas nonenveloped HEV virions have only been found in feces; however, no exhaustive studies have been performed to fully characterize HEV particles in blood.Methods: Using isopycnic ultracentrifugation, we determined the types of HEV particles in plasma of HEV-infected blood donors.Results: Nonenveloped HEV was detected in 8 of 23 plasma samples, whereas enveloped HEV was found in all of them. No association was observed between the presence of nonenveloped HEV and viral load, gender, or age at infection. However, samples with HEV-positive serology and/or increased levels of liver injury markers contained a higher proportion of nonenveloped HEV than samples with HEV-negative serology and normal levels of liver enzymes. These results were further confirmed by analyzing paired donation and follow-up samples of 10 HEV-infected donors who were HEV seronegative at donation but had anti-HEV antibodies and/or increased levels of liver enzymes at follow up.Conclusions: The HEV-contaminated blood products may contain nonenveloped HEV, which may pose an additional risk to blood safety by behaving differently to pathogen inactivation treatments or increasing infectivity. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

Author

Llorens-Revull, Meritxell, primary, Costafreda, Maria Isabel, additional, Rico, Angie, additional, Guerrero-Murillo, Mercedes, additional, Soria, Maria Eugenia, additional, Píriz-Ruzo, Sofía, additional, Vargas-Accarino, Elena, additional, Gabriel-Medina, Pablo, additional, Rodríguez-Frías, Francisco, additional, Riveiro-Barciela, Mar, additional, Perales, Celia, additional, Quer, Josep, additional, Sauleda, Silvia, additional, Esteban, Juan Ignacio, additional, and Bes, Marta, additional

Published
2021
Full Text
View/download PDF

26. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case‐Control Study.

Author

Piratvisuth, Teerha, Tanwandee, Tawesak, Thongsawat, Satawat, Sukeepaisarnjaroen, Wattana, Esteban, Juan Ignacio, Bes, Marta, Köhler, Bruno, He, Ying, Swiatek‐de Lange, Magdalena, Morgenstern, David, and Chan, Henry Lik‐Yuen

Subjects
INSULIN-like growth factor-binding proteins, HEPATOCELLULAR carcinoma, CHRONIC hepatitis B, HEPATITIS B, EXTRACELLULAR matrix proteins, LENTILS, VITAMIN K
Abstract

Hepatocellular carcinoma (HCC), the sixth most common cancer worldwide, has an incidence rate equal to mortality. Over 80% of HCC cases occur within a high‐risk population, mainly patients with both cirrhosis and chronic hepatitis B or C. With a 5‐year survival rate ranging from <16% for advanced HCC to >90% for early stage HCC, there is a high medical need for the early detection of HCC. In this study, we systematically evaluated biomarkers mentioned in international guidelines and peer‐reviewed literature for HCC surveillance and diagnosis with the aim of identifying combinations that display high sensitivity and specificity for early stage HCC. Fifty biomarkers were measured in the first sample panel, panel A (n = 110), and subjected to univariate analysis. Of these, 35 biomarkers (38 assays) from panel A and an additional 13 biomarkers from the literature were prioritized for subsequent multivariate evaluation with lasso regression and exhaustive search of two‐ to four‐biomarker combinations (panel B). Panel B included 1,081 samples from patients with HCC (n = 308) or with chronic liver diseases (n = 740). Among all patients, 61.0% had hepatitis B, 32.9% had hepatitis C, and 60.5% had cirrhosis; 40.6% of patients with HCC had early stage cancer. Protein induced by vitamin K absence‐II (PIVKA‐II; also known as des‐gamma‐carboxy prothrombin [DCP]) and alpha‐fetoprotein (AFP) demonstrated the best clinical performance, both individually and in combination, and the addition of a third biomarker (Lens culinaris agglutinin‐reactive fraction of AFP [AFP‐L3], cartilage oligomeric matrix protein [COMP], insulin‐like growth factor‐binding protein 3 [IGFBP3], or matrix metalloproteinase 3 [MMP3]) further increased sensitivity for the detection of both early stage and all‐stage HCC. The addition of age and sex to the three‐biomarker panel resulted in an improved diagnostic performance. Conclusion: The combination of AFP and PIVKA‐II, with either IGFBP3, COMP or MMP3, plus age and sex, demonstrated the best performance for the detection of early‐ and all‐stage HCC. These novel panels performed similar to that of the GALAD score (sex [gender], age, plus serum levels of AFP, AFP‐L3 and DCP [PIVKA‐II]), a promising screening tool developed for HCC detection. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

29. Identification and etiology-dependent evaluation of diagnostic algorithms for early detection of hepatocellular carcinoma

Author

Lange, Magdalena Swiatek-de, primary, Chan, Henry, additional, Piratvisuth, Teerha, additional, Tanwandee, Tawesak, additional, Thongsawat, Satawat, additional, Sukeepaisarnjaroen, Wattana, additional, Esteban Mur, Juan Ignacio, additional, Bes, Marta, additional, Köhler, Bruno, additional, Lisy, Marcus-Rene, additional, Belz, Christine Anna, additional, Rolny, Vinzent, additional, He, Ying, additional, and Morgenstern, Dave, additional

Published
2020
Full Text
View/download PDF

30. Unexpected long‐lasting anti‐HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?

Author

Riveiro‐Barciela, Mar, primary, Rando‐Segura, Ariadna, additional, Barreira‐Díaz, Ana, additional, Bes, Marta, additional, P. Ruzo, Sofía, additional, Piron, Maria, additional, Quer, Josep, additional, Sauleda, Silvia, additional, Rodríguez‐Frías, Francisco, additional, Esteban, Rafael, additional, and Buti, María, additional

Published
2020
Full Text
View/download PDF

31. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

Author

Chen, Qian, primary, Perales, Celia, additional, Soria, María Eugenia, additional, García-Cehic, Damir, additional, Gregori, Josep, additional, Rodríguez-Frías, Francisco, additional, Buti, María, additional, Crespo, Javier, additional, Calleja, José Luis, additional, Tabernero, David, additional, Vila, Marta, additional, Lázaro, Fernando, additional, Rando-Segura, Ariadna, additional, Nieto-Aponte, Leonardo, additional, Llorens-Revull, Meritxell, additional, Cortese, Maria Francesca, additional, Fernandez-Alonso, Irati, additional, Castellote, José, additional, Niubó, Jordi, additional, Imaz, Arkaitz, additional, Xiol, Xavier, additional, Castells, Lluís, additional, Riveiro-Barciela, Mar, additional, Llaneras, Jordi, additional, Navarro, Jordi, additional, Vargas-Blasco, Víctor, additional, Augustin, Salvador, additional, Conde, Isabel, additional, Rubín, Ángel, additional, Prieto, Martín, additional, Torras, Xavier, additional, Margall, Nuria, additional, Forns, Xavier, additional, Mariño, Zoe, additional, Lens, Sabela, additional, Bonacci, Martin, additional, Pérez-del-Pulgar, Sofía, additional, Londoño, Maria Carlota, additional, García-Buey, María Luisa, additional, Sanz-Cameno, Paloma, additional, Morillas, Rosa, additional, Martró, Elisa, additional, Saludes, Verónica, additional, Masnou-Ridaura, Helena, additional, Salmerón, Javier, additional, Quíles, Rosa, additional, Carrión, José Antonio, additional, Forné, Montserrat, additional, Rosinach, Mercè, additional, Fernández, Inmaculada, additional, García-Samaniego, Javier, additional, Madejón, Antonio, additional, Castillo-Grau, Pilar, additional, López-Núñez, Carme, additional, Ferri, María José, additional, Durández, Rosa, additional, Sáez-Royuela, Federico, additional, Diago, Moisés, additional, Gimeno, Concepción, additional, Medina, Rafael, additional, Buenestado, Juan, additional, Bernet, Albert, additional, Turnes, Juan, additional, Trigo-Daporta, Matilde, additional, Hernández-Guerra, Manuel, additional, Delgado-Blanco, Manuel, additional, Cañizares, Angelina, additional, Arenas, Juan Ignacio, additional, Gomez-Alonso, Maria Juana, additional, Rodríguez, Manuel, additional, Deig, Elisabet, additional, Olivé, Gemma, additional, Río, Oscar del, additional, Cabezas, Joaquín, additional, Quiñones, Ildefonso, additional, Roget, Mercè, additional, Montoliu, Silvia, additional, García-Costa, Juan, additional, Force, Lluís, additional, Blanch, Silvia, additional, Miralbés, Miguel, additional, López-de-Goicoechea, María José, additional, García-Flores, Angels, additional, Saumoy, María, additional, Casanovas, Teresa, additional, Baliellas, Carme, additional, Gilabert, Pau, additional, Martin-Cardona, Albert, additional, Roca, Rosa, additional, Barenys, Mercè, additional, Villaverde, Joana, additional, Salord, Silvia, additional, Camps, Blau, additional, Silvan di Yacovo, María, additional, Ocaña, Imma, additional, Sauleda, Silvia, additional, Bes, Marta, additional, Carbonell, Judit, additional, Vargas-Accarino, Elena, additional, Ruzo, Sofía P., additional, Guerrero-Murillo, Mercedes, additional, Von Massow, Georg, additional, Costafreda, María Isabel, additional, López, Rosa Maria, additional, González-Moreno, Leticia, additional, Real, Yolanda, additional, Acero-Fernández, Doroteo, additional, Viroles, Silvia, additional, Pamplona, Xavier, additional, Cairó, Mireia, additional, Ocete, María Dolores, additional, Macías-Sánchez, José Francisco, additional, Estébanez, Angel, additional, Quer, Joan Carles, additional, Mena-de-Cea, Álvaro, additional, Otero, Alejandra, additional, Castro-Iglesias, Ángeles, additional, Suárez, Francisco, additional, Vázquez, Ángeles, additional, Vieito, David, additional, López-Calvo, Soledad, additional, Vázquez-Rodríguez, Pilar, additional, Martínez-Cerezo, Francisco José, additional, Rodríguez, Raúl, additional, Macenlle, Ramiro, additional, Cachero, Alba, additional, Mereish, Gasshan, additional, Mora-Moruny, Carme, additional, Fábregas, Silvia, additional, Sacristán, Begoña, additional, Albillos, Agustín, additional, Sánchez-Ruano, Juan José, additional, Baluja-Pino, Raquel, additional, Fernández-Fernández, Javier, additional, González-Portela, Carlos, additional, García-Martin, Carmen, additional, Sánchez-Antolín, Gloria, additional, Andrade, Raúl Jesús, additional, Simón, Miguel Angel, additional, Pascasio, Juan Manuel, additional, Romero-Gómez, Manolo, additional, Antonio del-Campo, José, additional, Domingo, Esteban, additional, Esteban, Rafael, additional, Esteban, Juan Ignacio, additional, and Quer, Josep, additional

Published
2020
Full Text
View/download PDF

34. International Forum on Occult hepatitis B infection and transfusion safety

Author

Seed, Clive R., primary, Allain, Jean‐Pierre, additional, Lozano, Miquel, additional, Laperche, Syria, additional, Gallian, Pierre, additional, Gross, Sylvie, additional, Kwon, So‐Yong, additional, Oh, E.Y., additional, Kim, J.N., additional, Chua, Sze Sze, additional, Lam, Sally, additional, Ang, Ai Leen, additional, Tsoi, Wai‐Chiu, additional, Hewitt, Patricia E., additional, Davison, Katy L., additional, Tettmar, Kate, additional, O'Flaherty, Niamh, additional, Boland, Fiona, additional, Williams, Padraig, additional, Pomeroy, Louise, additional, Wendel, Silvano, additional, Fachini, Roberta, additional, Scuracchio, Patrícia, additional, Carminato, Patricia, additional, Fearon, Margaret, additional, O'Brien, Sheila F., additional, Delage, Gilles, additional, Kiely, Philip, additional, Hoad, Veronica, additional, Matsubayashi, Keiji, additional, Satake, Masahiro, additional, Taira, Rikizo, additional, Stramer, Susan L., additional, Sauleda, Silvia, additional, Bes, Marta, additional, Piron, Maria, additional, El Ekiaby, Magdy, additional, Vermeulen, Marion, additional, Levičnik Stezinar, Snežna, additional, Nograšek, Polona, additional, Jarvis, Lisa M., additional, Petrik, Juraj, additional, Charlewood, Richard, additional, Flanagan, Peter, additional, Grabarczyk, Piotr, additional, Kopacz, Aneta, additional, Łętowska, Magdalena, additional, Seifried, Erhard, additional, and Schmidt, Michael, additional

Published
2019
Full Text
View/download PDF

35. Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin

Author

Riveiro-Barciela, Mar, primary, Bes, Marta, additional, Quer, Josep, additional, Valcarcel, David, additional, Piriz, Sofia, additional, Gregori, Josep, additional, Llorens, Meritxell, additional, Salcedo, María-Teresa, additional, Piron, Maria, additional, Esteban, Rafael, additional, Buti, Maria, additional, and Sauleda, Silvia, additional

Published
2018
Full Text
View/download PDF

37. Correction for Quer at al., High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods

Author

Quer, Josep, primary, Gregori, Josep, additional, Rodríguez-Frias, Francisco, additional, Buti, Maria, additional, Madejon, Antonio, additional, Perez-del-Pulgar, Sofia, additional, Garcia-Cehic, Damir, additional, Casillas, Rosario, additional, Blasi, Maria, additional, Homs, Maria, additional, Tabernero, David, additional, Alvarez-Tejado, Miguel, additional, Muñoz, Jose Manuel, additional, Cubero, Maria, additional, Caballero, Andrea, additional, delCampo, Jose Antonio, additional, Domingo, Esteban, additional, Belmonte, Irene, additional, Nieto, Leonardo, additional, Lens, Sabela, additional, Muñoz-de-Rueda, Paloma, additional, Sanz-Cameno, Paloma, additional, Sauleda, Silvia, additional, Bes, Marta, additional, Gomez, Jordi, additional, Briones, Carlos, additional, Perales, Celia, additional, Sheldon, Julie, additional, Castells, Lluis, additional, Viladomiu, Lluis, additional, Salmeron, Javier, additional, Ruiz-Extremera, Angela, additional, Quiles-Pérez, Rosa, additional, Moreno-Otero, Ricardo, additional, López-Rodríguez, Rosario, additional, Allende, Helena, additional, Romero-Gómez, Manuel, additional, Guardia, Jaume, additional, Esteban, Rafael, additional, Garcia-Samaniego, Javier, additional, Forns, Xavier, additional, and Esteban, Juan Ignacio, additional

Published
2016
Full Text
View/download PDF

39. High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods

Author

Quer, Josep, primary, Gregori, Josep, additional, Rodríguez-Frias, Francisco, additional, Buti, Maria, additional, Madejon, Antonio, additional, Perez-del-Pulgar, Sofia, additional, Garcia-Cehic, Damir, additional, Casillas, Rosario, additional, Blasi, Maria, additional, Homs, Maria, additional, Tabernero, David, additional, Alvarez-Tejado, Miguel, additional, Muñoz, Jose Manuel, additional, Cubero, Maria, additional, Caballero, Andrea, additional, delCampo, Jose Antonio, additional, Domingo, Esteban, additional, Belmonte, Irene, additional, Nieto, Leonardo, additional, Lens, Sabela, additional, Muñoz-de-Rueda, Paloma, additional, Sanz-Cameno, Paloma, additional, Sauleda, Silvia, additional, Bes, Marta, additional, Gomez, Jordi, additional, Briones, Carlos, additional, Perales, Celia, additional, Sheldon, Julie, additional, Castells, Lluis, additional, Viladomiu, Lluis, additional, Salmeron, Javier, additional, Ruiz-Extremera, Angela, additional, Quiles-Pérez, Rosa, additional, Moreno-Otero, Ricardo, additional, López-Rodríguez, Rosario, additional, Allende, Helena, additional, Romero-Gómez, Manuel, additional, Guardia, Jaume, additional, Esteban, Rafael, additional, Garcia-Samaniego, Javier, additional, Forns, Xavier, additional, and Esteban, Juan Ignacio, additional

Published
2015
Full Text
View/download PDF

40. Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain)

Author

Sauleda, Sílvia, primary, Ong, Edgar, additional, Bes, Marta, additional, Janssen, Alanna, additional, Cory, Robin, additional, Babizki, Maria, additional, Shin, Tim, additional, Lindquist, Andre, additional, Hoang, Anh, additional, Vang, Lee, additional, Piron, Maria, additional, Casamitjana, Natàlia, additional, Koppelman, Marco, additional, Danzig, Lisa, additional, and Linnen, Jeffrey M., additional

Published
2014
Full Text
View/download PDF

41. Changes in Parvovirus B19 positivity rates in plasma units for fractionation: An unexpected effect of non‐pharmaceutical interventions against COVID‐19?

Author

Sauleda, Silvia, Piron, Maria, Bes, Marta, Martinez‐Llonch, Nuria, and Puig, Lluis

Subjects
PARVOVIRUS B19, OPTIMISM, NUCLEIC acid amplification techniques, HEMAPHERESIS, COVID-19
Abstract

However, between January 2020 and July 2021, the plasma fractionator has reported only three plasma units positive for B19, from three whole blood donors, one male and two females that donated on 18 January, and 17 and 28 February 2020. Parvovirus B19 (B19) is a small non-enveloped DNA virus, discovered in 1975 by Yvonne Cossart in the blood of a healthy blood donor. B19 infections follow a seasonal pattern in plasma donors, most positive plasma units corresponding to donations obtained between March and July [1]. [Extracted from the article]

Published
2022
Full Text
View/download PDF

42. Identification of host and viral factors involved in a dissimilar resolution of a hepatitis C virus infection

Author

Cubero, Maria, primary, Gregori, Josep, additional, Esteban, Juan I., additional, García-Cehic, Damir, additional, Bes, Marta, additional, Perales, Celia, additional, Domingo, Esteban, additional, Rodríguez-Frías, Francisco, additional, Sauleda, Silvia, additional, Casillas, Rosario, additional, Sanchez, Alex, additional, Ortega, Israel, additional, Esteban, Rafael, additional, Guardia, Jaume, additional, and Quer, Josep, additional

Published
2013
Full Text
View/download PDF

46. High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods

Author

Quer, Josep, Gregori, Josep, Rodríguez-Frias, Francisco, Buti, Maria, Madejon, Antonio, Perez-del-Pulgar, Sofia, Garcia-Cehic, Damir, Casillas, Rosario, Blasi, Maria, Homs, Maria, Tabernero, David, Alvarez-Tejado, Miguel, Muñoz, Jose Manuel, Cubero, Maria, Caballero, Andrea, delCampo, Jose Antonio, Domingo, Esteban, Belmonte, Irene, Nieto, Leonardo, Lens, Sabela, Muñoz-de-Rueda, Paloma, Sanz-Cameno, Paloma, Sauleda, Silvia, Bes, Marta, Gomez, Jordi, Briones, Carlos, Perales, Celia, Sheldon, Julie, Castells, Lluis, Viladomiu, Lluis, Salmeron, Javier, Ruiz-Extremera, Angela, Quiles-Pérez, Rosa, Moreno-Otero, Ricardo, López-Rodríguez, Rosario, Allende, Helena, Romero-Gómez, Manuel, Guardia, Jaume, Esteban, Rafael, Garcia-Samaniego, Javier, Forns, Xavier, and Esteban, Juan Ignacio

Abstract

ABSTRACTHepatitis C virus (HCV) is classified into seven major genotypes and 67 subtypes. Recent studies have shown that in HCV genotype 1-infected patients, response rates to regimens containing direct-acting antivirals (DAAs) are subtype dependent. Currently available genotyping methods have limited subtyping accuracy. We have evaluated the performance of a deep-sequencing-based HCV subtyping assay, developed for the 454/GS-Junior platform, in comparison with those of two commercial assays (Versant HCV genotype 2.0 and Abbott Real-time HCV Genotype II) and using direct NS5B sequencing as a gold standard (direct sequencing), in 114 clinical specimens previously tested by first-generation hybridization assay (82 genotype 1 and 32 with uninterpretable results). Phylogenetic analysis of deep-sequencing reads matched subtype 1 calling by population Sanger sequencing (69% 1b, 31% 1a) in 81 specimens and identified a mixed-subtype infection (1b/3a/1a) in one sample. Similarly, among the 32 previously indeterminate specimens, identical genotype and subtype results were obtained by direct and deep sequencing in all but four samples with dual infection. In contrast, both Versant HCV Genotype 2.0 and Abbott Real-time HCV Genotype II failed subtype 1 calling in 13 (16%) samples each and were unable to identify the HCV genotype and/or subtype in more than half of the non-genotype 1 samples. We concluded that deep sequencing is more efficient for HCV subtyping than currently available methods and allows qualitative identification of mixed infections and may be more helpful with respect to informing treatment strategies with new DAA-containing regimens across all HCV subtypes.

Published
2014
Full Text
View/download PDF

47. THU470 - Identification and etiology-dependent evaluation of diagnostic algorithms for early detection of hepatocellular carcinoma.

Author

Lange, Magdalena Swiatek-de, Chan, Henry, Piratvisuth, Teerha, Tanwandee, Tawesak, Thongsawat, Satawat, Sukeepaisarnjaroen, Wattana, Esteban Mur, Juan Ignacio, Bes, Marta, Köhler, Bruno, Lisy, Marcus-Rene, Belz, Christine Anna, Rolny, Vinzent, He, Ying, and Morgenstern, Dave

Subjects
*HEPATOCELLULAR carcinoma, *IDENTIFICATION, *ALGORITHMS
Published
2020
Full Text
View/download PDF

48. HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience.

Author

Piron M, Salvador F, Caballero E, Sánchez-Montalvá A, Bes M, Casamitjana N, Puig L, Molina I, and Sauleda S

Subjects
Adult, Deltaretrovirus, Female, Human T-lymphotropic virus 2, Humans, Male, Spain epidemiology, Blood Donors, HTLV-I Infections diagnosis, HTLV-I Infections epidemiology, HTLV-II Infections diagnosis, HTLV-II Infections epidemiology, Human T-lymphotropic virus 1 genetics
Abstract

Human T-cell lymphotropic virus type 1 and 2 (HTLV-1/2) screening is not mandatory in Spanish blood banks. In Catalonia, selective screening was introduced in 2008, followed by universal screening in 2011. We present herein a 10-year experience of HTLV testing in blood donors. HTLV-1/2 selective screening was performed using Ortho-Clinical Diagnostics HTLV-I/HTLV-II Ab-Capture ELISA between February 2008 and May 2009, then Abbott Prism HTLV-I/ HTLV-II assay until December 2010. Abbott Architect rHTLV-I/II assay was then used for HTLV-1/2 universal screening in pooled samples. INNO-LIA HTLV I/II Score (Fujirebio) and in-house HTLV-1/2 proviral DNA real-time PCR were used in reactive samples. Follow-up was offered to confirm HTLV-1/2 donors in Vall d'Hebron Hospital. Between 2008 and 2017, 51 blood donors were confirmed HTLV positive (46 HTLV-1, 4 HTLV-2 and 1 HTLV) out of 2,114,891 blood donations (1 in 41,468). Sixty-nine percent were female, median age was 40 years and most were born in Latin America (69%), followed by Europe (25%), Africa (4%) and Asia (2%). Screening of relatives and partners identified 12 additional HTLV-1 cases. Lookback studies did not show any HTLV-1/2 transmission. HTLV infections found in blood donors mirror epidemiological changes in the population of Spain. Consequently, HTLV should be considered a potential risk for recipients and calls for the design of optimal strategies to ensure transfusion safety., Competing Interests: The authors declare no conflict of interest.

Published
2022
Full Text
View/download PDF

49. SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).

Author

Piron M, Jané M, Ciruela P, Basile L, Martínez A, Puig L, Bes M, and Sauleda S

Subjects
Antibodies, Viral, Blood Donors, Communicable Disease Control, Humans, Immunoglobulin G, Immunoglobulin M, Pandemics, Prospective Studies, Retrospective Studies, Seroepidemiologic Studies, Spain epidemiology, COVID-19 epidemiology, SARS-CoV-2
Abstract

Background: Due to the COVID-19 pandemic, a national lockdown was applied in Spain from March to May 2020. It is uncertain when SARS-CoV-2 started to circulate in Catalonia, and only a few cases were diagnosed in this period. We assessed the SARS-CoV-2 seroprevalence in blood donors before and after the first wave and compared it with public health service (PHS) data., Materials and Methods: Retrospective archive or prospective fresh blood samples were obtained from blood donors aged 18 to 70 and anonymized after demographic data had been recorded (gender, age, place of residence, blood collection date). Two CE-marked enzyme-linked immunosorbent assays were used to test for anti-SARS-CoV-2. A SARS-CoV-2 IgM test was additionally performed in positive samples. Individuals aged 18 to 70 from among the general population diagnosed as having SARS-CoV-2 by the PHS were included for comparison with blood donor results., Results: A total of 10,170 blood donations were included in the first period, between 24 February and 9 March 2020, and 6,829 in the second period, between 16 May and 17 June 2020. The observed SARS-CoV-2 seroprevalence among blood donors rose from 0.27% (95% CI: 0.18-0.39) before the first wave to 5.55% (95% CI: 5.03-6.12) after it, and was even higher (6.90% [95% CI: 5.64-8.41]) among blood donors aged 18 to 29. The seroprevalence among blood donors was higher in more populated areas (Barcelona: 7.69%). A comparison of blood donor data with officially diagnosed cases showed a global 87.44% underestimation of SARS-CoV-2 in June 2020., Discussion: We analyzed the explosive 3-month increase in blood donor SARS-CoV-2 seroprevalence (from 0.27% to 5.55%) and show that more than 87% of cases went undiagnosed, despite the unprecedented deployment of testing measures. SARS-CoV-2 IgM results suggest that the virus was circulating among blood donors in February 2020. Blood donors are definitively proven to be a valuable resource for emerging disease surveillance studies.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results